Home > Resources > Company Profiles > Elan Corporation PLC

Elan Corporation PLC (ELN)

Your Name

Your Email Address *
Send a copy to me

Recipient's Email Address *

Separate multiple email addresses (max 20) with commas.

Subject *

Message

0/1500

Enter the text you see in the image *

Letters are not case-sensitive, disregard spaces.

Try a New One

This helps us prevent automated registrations and spamming.

Email Confirmation

G. Kelly Martin , CEO/President/Director

www.elan.com

Industry: Healthcare

OPEN

LAST

PREV CLOSE

CHANGE

VOLUME

Overview

News

People

Financials

Overview

A neuroscience-based biotechnology company operates into two business units: Biopharmaceuticals and Elan Drug Technologies.

News Feeds

Elan climbs to 6-year high on study results AP
Jun 17 2008
Wyeth, Elan shares rise on Alzheimer's drug results AP
Jun 17 2008
Wyeth Alzheimer's drug fails to meet goal in trial AP
Jun 17 2008
Analyst awaits data on Wyeth-Elan Alzheimer's drug AP
Jun 16 2008

Press Releases

Zacks Analyst Blog Highlights: Transition Therapeutics, Elan, Eli Lilly, Burger King and McDonald's. Jun-27-2008, 06:00AM EDT
Elan and Wyeth Announce Encouraging Top-line Results from Phase 2 Clinical Trial of Bapineuzumab for Alzheimer's Disease Jun-17-2008, 02:00AM EDT
Elan to Present at Goldman Sachs Global Healthcare Conference Jun-05-2008, 02:00AM EDT
Elan Announces Changes in Board of Directors May-22-2008, 04:30PM EDT
Elan Reports First Quarter 2008 Financial Results Apr-24-2008, 02:00AM EDT

News From Around the Web

News

Stocks That Pay You Back (Motley Fool)

Jul 03 2008
Analyst awaits data on Wyeth-Elan Alzheimer's drug (Boston Globe)

Jul 01 2008
ADRs in Focus: Elan climbs to 6-year high (Boston Globe)

Jun 23 2008
Closing Glance: Pharmaceuticals (Boston Globe)

Jun 19 2008
Elan announces encouraging results from Alzheimer drug trials (Emigrant Online, Ireland)

Jun 18 2008
Movers roundup: CME Group, Wyeth-Elan (Boston Globe)

Jun 17 2008
Wyeth, Elan shares rise on Alzheimer's drug results (Boston Globe)

Jun 17 2008
Elan and Wyeth Announce Encouraging Top-line Results from Phase 2 Clinical Trial of Bapineuzumab for Alzheimer's Disease (Drugs.com)

Jun 17 2008
Wyeth Alzheimer's drug fails to meet goal in trial (Boston Globe)

Jun 17 2008

Blogs

Readers Get Short With Me--Over Amgen (CNBC: Pharmas Market with Mike Huckman)

Jul 03 2008

Employees

Number of Employees: 1,610

Revenue per Employee: $358,535

Top Executives

Richard Collier, Executive VP/General Counsel

Dr. Ivan Lieberburg, MD, PhD, Executive VP/Chief Medical Officer

Dr. Allison Hulme, PhD, Divisional Executive VP/Other Corporate Officer

Dr. Menghis Bairu, MD, Senior VP/Other Corporate Officer

Dr. James Callaway, PhD, Senior VP/Other Corporate Officer

Dr. Johannes Roebers, PhD, Senior VP/Other Corporate Officer

Paul V. Breen, Divisional Executive VP

Dr.Ted Yednock, PhD, Executive VP/Other Corporate Officer

Kathleen Martorano, Executive VP, Divisional/Other Corporate Officer

Dr. David W. Feigal, Jr, MD, Other Corporate Officer/Senior VP

Nigel Clerkin, Senior VP, Divisional/Other Corporate Officer/Chief Accounting Officer

Dr. Dale Schenk, PhD, Chief Scientific Officer/Executive VP

Karen S. Kim, Divisional Executive VP

Board of Directors

Jonas Frick, Director

Kieran McGowan, Director

William R. Rohn, Director

Ann Maynard Gray, Director

William F. Daniel, Secretary/Executive VP

Laurence G. Crowley, Director

Jeffrey Shames, Director

Gary Kennedy, Director

Shane Cooke, Director/CFO/Executive VP/Other Corporate Officer

Dr. Dennis J. Selkoe, MD, Director

Dr.Floyd E. Bloom, Director

Dr.Lars Ekman, M.D., Ph.D., Director

Giles Kerr, Director

Kyran McLaughlin, Chairman of the Board/Director

Financials

Quarterly

Annual

Income Statement	04/2008	02/2008	11/2007	09/2007
Sales	114.7 Mil.	97.2 Mil.	176.5 Mil.	-65.6 Mil.
Gross Operating Profit	100 Mil.	121.1 Mil.	100 K.	168.3 Mil.
Operating Income before D & A (EBITDA)	-42.6 Mil.	-40.7 Mil.	-155.3 Mil.	-79.5 Mil.
Total Income Before Interest Expenses (EBIT)	-48.9 Mil.	-46.3 Mil.	-63.4 Mil.	-132.8 Mil.
Total Net Income	-85.5 Mil.	-83.5 Mil.	-87.4 Mil.	-189.6 Mil.
Basic EPS, Total	-0.18	-0.18	-0.19	-0.4
Diluted EPS, Total	-0.18	-0.18	-0.19	-0.4

BALANCE STATEMENT	04/2008	02/2008	11/2007	09/2007
Cash and Equivalents	548.9 Mil.	423.5 Mil.	784.8 Mil.	826 Mil.
Total Assets	875.3 Mil.	916.4 Mil.	993.8 Mil.	1.01 Bil.
Total Liabilities	251.6 Mil.	NA	263.4 Mil.	200.1 Mil.
Total Capitalization	1.47 Bil.	1.53 Bil.	1.59 Bil.	1.7 Bil.

Cash Flow	04/2008	02/2008	11/2007	09/2007
Net Cash From Continuing Operations	-67.3 Mil.	NA	-108.7 Mil.	-59.7 Mil.
Net Cash From Investing Activities	178 Mil.	NA	-8.5 Mil.	-8.5 Mil.
Net Cash From Financing Activities	14.7 Mil.	NA	-608.6 Mil.	-616 Mil.
Net Change in Cash & Cash Equivalents	125.4 Mil.	NA	-725.8 Mil.	-684.6 Mil.

Income Statement	2008	2007	2006	2005
Sales	337.9 Mil.	112.7 Mil.	115.8 Mil.	96.9 Mil.
Gross Operating Profit	421.5 Mil.	447.7 Mil.	374.5 Mil.	384.8 Mil.
Operating Income before D & A (EBITDA)	-180.7 Mil.	-131.3 Mil.	-217.2 Mil.	-213 Mil.
Total Income Before Interest Expenses (EBIT)	-285 Mil.	-114.3 Mil.	-257.5 Mil.	-306.4 Mil.
Total Net Income	-405 Mil.	-267.3 Mil.	-383.6 Mil.	-394.7 Mil.
Basic EPS, Total	-0.86	-0.62	-0.93	-1.01
Diluted EPS, Total	-0.86	-0.62	-0.93	-1.01

BALANCE STATEMENT	2008	2007	2006	2005
Cash and Equivalents	423.5 Mil.	1.51 Bil.	1.08 Bil.	1.35 Bil.
Total Assets	916.4 Mil.	1.76 Bil.	1.25 Bil.	1.73 Bil.
Total Liabilities	NA	851.5 Mil.	246.6 Mil.	440.3 Mil.
Total Capitalization	1.53 Bil.	1.85 Bil.	2.03 Bil.	2.46 Bil.

Cash Flow	2008	2007	2006	2005
Net Cash From Continuing Operations	NA	-238.7 Mil.	-283.5 Mil.	-347.9 Mil.
Net Cash From Investing Activities	NA	34.7 Mil.	120.9 Mil.	474.2 Mil.
Net Cash From Financing Activities	NA	629.3 Mil.	-99.7 Mil.	441.5 Mil.
Net Change in Cash & Cash Equivalents	NA	429.9 Mil.	-266.9 Mil.	569.4 Mil.

Elan Corporation PLC (ELN)

Company Information

Overview

Employees

Top Executives

Board of Directors

Financials

Company Profile Change Request